PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Type 3 resistant starch (Ce-RS3) significantly decreased levels of total cholesterol, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol over 12 weeks [PMID:38825157].
Acylated Canna edulis starch (butyrylated and valeroylated) improved metrics of weight reduction, blood glucose, insulin resistance, and lipid metabolism in animal models [PMID:40829682].
Canna starch intake prevented the decrease in body temperature associated with anaphylactic response in ovalbumin-induced food allergy mice [PMID:38397452].
Canna edulis RS3 significantly reduced climbing time and alleviated neuroinflammation and apoptosis in the substantia nigra [PMID:39347419].
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 39447808 (2024) — Structural, morphological, compositional, thermal, pasting, and functional properties of isolated Achira (Canna indica L.) starch: Review. · International journal of biological macromolecules
- 2.PMID: 19627148 (2009) — Characterization of starch from two ecotypes of andean achira roots (Canna edulis). · Journal of agricultural and food chemistry
- 3.PMID: 33678878 (2021) — Dual modification of achira (Canna indica L) starch and the effect on its physicochemical properties for possible food applications. · Journal of food science and technology
- 4.PMID: 16187013 (2005) — Chemical composition, mineral profile, and functional properties of Canna (Canna edulis) and Arrowroot (Maranta spp.) starches. · Plant foods for human nutrition (Dordrecht, Netherlands)
- 5.PMID: 37016689